Stage IV Cutaneous Melanoma AJCC v6 and v7
39
0
15
16
Key Insights
Highlights
Success Rate
73% trial completion
Published Results
24 trials with published results (62%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
15.4%
6 terminated out of 39 trials
72.7%
-13.8% vs benchmark
5%
2 trials in Phase 3/4
150%
24 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (39)
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
Dinaciclib in Treating Patients With Stage IV Melanoma
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction